The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1306
Conjugated Estrogens (Premarin) Vaginal Cream
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

An old conjugated estrogens vaginal cream (Premarin Vaginal Cream – Wyeth) has been newly approved by the FDA specifically for treatment of moderate to severe dyspareunia due to vulvar and vaginal atrophy associated with menopause. Synthetic conjugated estrogens A vaginal cream (Barr) has also been approved for this indication, but has not yet been marketed.

Vulvovaginal Atrophy – Other vaginal estrogens are approved for treatment of vulvovaginal atrophy, but not specifically for dyspareunia. Vulvovaginal atrophy is common among postmenopausal women and causes itching, dryness and pain with intercourse. Systemic estrogen (tablets, patches, etc.) effectively treats the symptoms of vaginal atrophy, but the risks of such treatment include breast cancer, venous thromboembolism and stroke.1

PHARMACOLOGY — Each gram of the cream contains 0.625 mg of conjugated ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Conjugated Estrogens (Premarin) Vaginal Cream
Article code: 1306b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian